Drug recall · January 15, 2020
Ranitidine Capsules 150 mg recall
Why: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.
- Lots / codes
Batch # 1905225VN, exp. date Apr-2021 1905226VD, exp. date Apr-2021 1906295UN, exp. date May-2021 1906296UN, exp. date May-2021 1906297UN, exp. date May-2021 1906298UD, exp. date May-2021
- Quantity
- 624 bottes
- Company
- Appco Pharma LLC, Piscataway, NJ
- Distribution
- Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.
- Initiated
- January 7, 2020 · Voluntary: Firm initiated
- Classified
- January 7, 2020
- Reported
- January 15, 2020
- Ended
- April 24, 2020
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.